1.85
+0.05(+2.78%)
Currency In USD
| Previous Close | 1.8 |
| Open | 1.78 |
| Day High | 1.86 |
| Day Low | 1.75 |
| 52-Week High | 5.09 |
| 52-Week Low | 1.72 |
| Volume | 745,754 |
| Average Volume | 227,741 |
| Market Cap | 111.15M |
| PE | -1.34 |
| EPS | -1.38 |
| Moving Average 50 Days | 2.5 |
| Moving Average 200 Days | 2.91 |
| Change | 0.05 |
If you invested $1000 in Acumen Pharmaceuticals, Inc. (ABOS) since IPO date, it would be worth $92.04 as of December 22, 2024 at a share price of $1.85. Whereas If you bought $1000 worth of Acumen Pharmaceuticals, Inc. (ABOS) shares 2 years ago, it would be worth $332.73 as of December 22, 2024 at a share price of $1.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
GlobeNewswire Inc.
Nov 26, 2024 9:00 PM GMT
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
GlobeNewswire Inc.
Nov 11, 2024 9:00 PM GMT
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
GlobeNewswire Inc.
Nov 06, 2024 9:00 PM GMT
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer